FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely rheumatology, and may be used for treating a joint injury in an individual suffering rheumatoid arthritis (RA). For this purpose, rituximab is introduced into the patient showing no adequate response or having oversensitivity to one or more tumour necrosis factor (TNF) inhibitors. At least one therapeutic course of rituximab is prescribed to the patient, and the treatment involves at least one more therapeutic course of rrituximab. The additional therapeutic course is conducted 24 weeks after the beginning of the previous therapeutic course of rituximab. Each course includes the introduction of two intravenous doses 1000 mg every 14 days. Also, the method involves the radiographic analysis 52 weeks after the introduction of rituximab.
EFFECT: group of inventions provides relieving the joint injury in the specified group of patients.
9 cl, 46 dwg, 2 tbl, 5 ex
